[Skip to Content]
[Skip to Content Landing]
Views 2,511
Citations 0
News From the Food and Drug Administration
January 1/8, 2019

New Acute Myeloid Leukemia Therapy

JAMA. 2019;321(1):23. doi:10.1001/jama.2018.20416

The FDA has approved 2 new acute myeloid leukemia (AML) treatments: one for older adults who cannot undergo intensive chemotherapy and another for patients with a certain genetic mutation.

Glasdegib tablets are indicated for use in combination with a low dose of the chemotherapy medication cytarabine in adults aged 75 years or older with newly diagnosed AML. The combination is intended to help older adults who can’t tolerate intensive chemotherapy’s toxicities, said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence.